169 / 1068
Polish II – Trial
(randomized phase III)
High-risk criteria: fixed T3 or T4 („nonresectable“)
RT 50.4 Gy +
Bolus 5-FU/LV 1.+ 5. week
50 mg/m
2
Oxaliplatin once weekly
T
M
E
Wk 12
R
5 x 5
Gy
FOLFOX 4
3#, q14
T
M
E
Wk 12
Primary endpoint: R0 resection rate (75% > 85%), 540 pts. required